Urgent.News

What's breaking now, across thousands of outlets.

Editions

Finance & Markets

Flowers Foods Q2 2026 slides: volume drop drives 19% EBITDA decline

Flowers Foods Q2 2026 slides: volume drop drives 19% EBITDA decline

Flowers Foods reported a 4.0% decline in net sales for Q2 2026, driven by a 5.8% volume drop, which led to a 19.2% decrease in adjusted EBITDA to $111.3 million. The company's full-year outlook was also revised downward due to broad-based sales weakness across Branded Retail and Other segments, with the latter segment experiencing a 4.4% sales decline.

Despite these challenges, Flowers Foods outlined a strategic response plan focused on brand relaunch and innovation, including updating the Nature's Own brand and introducing Non-GMO Project Verified status, as well as investing in capital expenditures.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

In Healthcare ETFs, Is iShares Pharma a Better Buy Than VanEck Biotech?

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma exposure delivered a 1.4% dividend yield and lower drawdown risk.

  • iShares Pharma (IHE) focuses on established pharmaceutical companies
  • VanEck Biotech (BBH) targets high-growth biotechnology firms
  • BBH's beta is higher than IHE, indicating more volatility

More from Thursday 20 August →